The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...